Total Payments
$27,703
2024 Payments
$10,570
Companies
27
Transactions
122
Medicare Patients
1,176
Medicare Billing
$100,631
Payment Breakdown by Category
Other$20,490 (74.0%)
Food & Beverage$2,705 (9.8%)
Travel$2,399 (8.7%)
Research$2,110 (7.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $12,500 | 5 | 45.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,990 | 3 | 28.8% |
| Food and Beverage | $2,705 | 87 | 9.8% |
| Travel and Lodging | $2,399 | 6 | 8.7% |
| Unspecified | $2,110 | 21 | 7.6% |
Payments by Type
General
$25,593
101 transactions
Research
$2,110
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $9,523 | 9 | $0 (2021) |
| Tolmar, Inc. | $8,290 | 4 | $0 (2024) |
| Clarus Therapeutics Inc. | $4,580 | 10 | $0 (2021) |
| ABBVIE INC. | $2,129 | 22 | $0 (2024) |
| Verity Pharmaceuticals Inc. | $1,000 | 1 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $332.83 | 15 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $248.62 | 5 | $0 (2021) |
| Dexcom, Inc. | $197.06 | 12 | $0 (2023) |
| Medtronic MiniMed, Inc. | $142.62 | 2 | $0 (2019) |
| Abbott Laboratories | $134.89 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,570 | 18 | Tolmar, Inc. ($8,290) |
| 2023 | $76.69 | 4 | Abbott Laboratories ($37.13) |
| 2022 | $481.59 | 15 | Radius Health, Inc. ($125.00) |
| 2021 | $6,932 | 28 | Acerus Pharmaceuticals Corporation ($6,598) |
| 2020 | $7,517 | 12 | Clarus Therapeutics Inc. ($4,545) |
| 2019 | $1,392 | 27 | AbbVie, Inc. ($848.85) |
| 2018 | $608.66 | 17 | Boehringer Ingelheim Pharmaceuticals, Inc. ($218.45) |
| 2017 | $125.00 | 1 | Corcept Therapeutics ($125.00) |
All Payment Transactions
122 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | Verity Pharmaceuticals Inc. | Tlando (Drug) | Honoraria | Cash or cash equivalent | $1,000.00 | General |
| Category: Testosterone Replacement Therapy (TRT) | ||||||
| 06/15/2024 | Tolmar, Inc. | JATENZO (Drug) | Honoraria | Cash or cash equivalent | $4,000.00 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 06/15/2024 | Tolmar, Inc. | JATENZO (Drug) | Travel and Lodging | Cash or cash equivalent | $789.54 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 06/04/2024 | Tolmar, Inc. | JATENZO (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 06/04/2024 | Tolmar, Inc. | JATENZO (Drug) | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $309.74 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $69.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $125.05 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $70.25 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | — | — | In-kind items and services | $26.25 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ||||||
| 09/27/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: Diabetes Care | ||||||
| 08/29/2023 | Abbott Laboratories | FREESTYLE LIBRE 2 (Device) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Diabetes Care | ||||||
| 04/27/2023 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $18.72 | General |
| 04/14/2023 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Endocrinology | ||||||
| 12/19/2022 | Radius Health, Inc. | Tymlos (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Endocrinology | ||||||
| 12/15/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: Diabetes Care | ||||||
| 12/09/2022 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $1,280 | 13 |
| M16-100 | AbbVie, Inc. | $829.77 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 262 | 342 | $45,969 | $20,272 |
| 2022 | 6 | 250 | 387 | $44,792 | $23,986 |
| 2021 | 12 | 384 | 534 | $65,416 | $35,171 |
| 2020 | 9 | 280 | 358 | $39,353 | $21,202 |
Total Patients
1,176
Total Services
1,621
Medicare Billing
$100,631
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 68 | 85 | $14,436 | $6,320 | 43.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 51 | $5,661 | $3,171 | 56.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 33 | 40 | $7,686 | $2,917 | 38.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 47 | $5,492 | $2,566 | 46.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 15 | $4,237 | $1,726 | 40.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 24 | 25 | $2,750 | $1,295 | 47.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 12 | $2,544 | $1,227 | 48.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 14 | 25 | $1,987 | $650.88 | 32.8% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 41 | 42 | $1,176 | $399.84 | 34.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 107 | 170 | $25,500 | $15,049 | 59.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 45 | 54 | $6,696 | $3,436 | 51.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 38 | $4,218 | $2,025 | 48.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $3,450 | $1,679 | 48.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 21 | 42 | $3,024 | $1,149 | 38.0% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 51 | 68 | $1,904 | $648.26 | 34.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 117 | 185 | $28,090 | $16,904 | 60.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 61 | $6,771 | $3,421 | 50.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 22 | 22 | $4,890 | $2,585 | 52.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 36 | 41 | $4,790 | $2,511 | 52.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 16 | $3,392 | $1,734 | 51.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 12 | $2,665 | $1,674 | 62.8% |
| 95250 | Ambulatory continuous glucose (sugar) monitoring for a minimum of 72 hours | Office | 2021 | 15 | 15 | $3,675 | $1,608 | 43.8% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 36 | 57 | $4,104 | $1,426 | 34.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 18 | 19 | $2,765 | $1,243 | 45.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 17 | 18 | $1,834 | $1,136 | 62.0% |
About Dr. Sandeep Dhindsa, M.D
Dr. Sandeep Dhindsa, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1881747301.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sandeep Dhindsa, M.D has received a total of $27,703 in payments from pharmaceutical and medical device companies, with $10,570 received in 2024. These payments were reported across 122 transactions from 27 companies. The most common payment nature is "Honoraria" ($12,500).
As a Medicare-enrolled provider, Dhindsa has provided services to 1,176 Medicare beneficiaries, totaling 1,621 services with total Medicare billing of $100,631. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Saint Louis, MO
- Active Since 01/19/2007
- Last Updated 01/26/2021
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1881747301
Products in Payments
- JATENZO (Drug) $12,869
- Natesto (Drug) $9,523
- ARMOUR THYROID (Drug) $1,229
- Tlando (Drug) $1,000
- Androgel (Drug) $829.77
- JARDIANCE (Drug) $376.88
- FARXIGA (Drug) $248.62
- Minimed 670G System (Device) $164.94
- XYOSTED (Drug) $129.62
- Korlym (Drug) $125.00
- Tymlos (Biological) $125.00
- Omnia (Device) $118.64
- Dexcom G6 Transmitter (Medical Supply) $103.88
- DEXCOM G6 TRANSMITTER (Device) $93.18
- Ozempic (Drug) $67.20
- SOLIQUA (Drug) $65.00
- AFREZZA (Drug) $59.92
- CYCLOSET (Drug) $58.41
- FreeStyle Lite system (Device) $49.66
- FREESTYLE LIBRE (Device) $48.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Saint Louis
Dr. Janet Mcgill, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $404,181
Endocrinology, Diabetes & Metabolism $404,181
Dr. Jonathan Bortz, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $220,321
Endocrinology, Diabetes & Metabolism $220,321
Farid Roman, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $157,339
Endocrinology, Diabetes & Metabolism $157,339
Dr. Kathryn Diemer, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $147,082
Endocrinology, Diabetes & Metabolism $147,082
Dr. Garry Tobin, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $122,345
Endocrinology, Diabetes & Metabolism $122,345
Dr. Michael Berk, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $99,949
Endocrinology, Diabetes & Metabolism $99,949